DUBLIN--(BUSINESS WIRE)--Dec. 12, 2012--
Elan Corporation, plc (NYSE: ELN) announces that, at an Extraordinary
General Meeting (EGM) held earlier today, the sole ordinary resolution
to approve the demerger of the Prothena Business was duly passed. The
full text of the resolution was included in the notice of the EGM dated
November 12, 2012 which is available on the Company’s website. The
details of the votes lodged by proxy are also available on www.elan.com
Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology
company committed to making a difference in the lives of patients and
their families by dedicating itself to bringing innovations in science
to fill significant unmet medical needs that continue to exist around
the world. Elan shares trade on the New York and Irish Stock Exchanges.
For additional information about the Company, please visit www.elan.com.
Source: Elan Corporation
Ph: + 353-1-709-4444
Ph: + 353-1-709-4022